- FDA approves easy-to-use injectable methotrexate for RA, psoriasis, juvenile arthritis
- Antares announces availability of injectable methotrexate product for arthritis, psoriasis
- Otezla approved for the treatment of adult patients with active psoriatic arthritis
- Sandoz starts late-stage trial of Humira biosimilar
- FDA approves UCB's Cimzia for ankylosing spondylitis
SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by Abbott for treating ulcerative colitis.
The agency announced Friday the approval of Humira (adalimumab) for moderate to severe UC. The drug was already approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, plaque psoriasis and juvenile idiopathic arthritis.
UC is a chronic disease that affects about 620,000 Americans, according to the National Institutes of Health.